Breast Cancer, Neuroendocrine Tumors, Prostate Cancer
Conditions
Brief summary
The purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER) by collecting data from PET scans using one of three different imaging agents: 18F-PSMA; 18F-FES; or, 68Ga DOTATATE. These imaging agents are approved by the FDA to be used for patients diagnosed with prostate cancer (18F-PSMA), neuroendocrine tumor (68Ga DOTATATE), or breast cancer (18F-FES).
Interventions
DIAGNOSTIC_TESTTotal-body PET imaging
Total-body PET imaging at different timepoints
Sponsors
University of California, Davis
Lantheus Medical Imaging
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
18F-PSMA (n=3) and 68Ga-PSMA (n=3) Inclusion criteria: * Persons \>18 yo with suspected prostate cancer metastasis * Prior imaging study (CT, and/or MRI and/or Bone scan and/or Fluciclovine scan) suspicious for metastatic disease, obtained within 4 months from the research scan date. 68Ga DOTATATE (n=3) or 64Cu-DOTATATE (n=3) Inclusion Criteria: * Persons \> 18 yo suspicious for or diagnosed with somatostatin receptor positive neuroendocrine tumors (NETs) * Prior DOTATATE PET/CT scan suspicious for tumor obtained not earlier than 4 months from the research scan date.
Exclusion criteria
• Recent administration of long-acting somatostatin analogs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| measure radiotracer avidity | One study imaging visit lasting up to 10 hours | measure radiotracer avidity, i.e. standardized uptake value measurements (SUV max and mean) of tumor and normal tissue as a function of time with 18F-PSMA, 18F-FES, 68Ga DOTATATE in a total-body PET scanner among men with suspected prostate cancer metastasis, patients suspicious for or diagnosed with somatostatin receptor positive neuroendocrine tumors, and patients with recurrent or metastatic breast cancer. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORLorenzo Nardo, MD
University of California, Davis
Outcome results
None listed